

Attorney Docket No.: 5087.304-US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Noguchi et al.

Confirmation No: 9126

Serial No.: 09/371,343

Group Art Unit: 1731

Filed: August 10, 1999

Examiner: Alvo, M.

For: Method For Producing Cellulose Derivatives

## STATEMENT UNDER 37 CFR 1.97(e)


Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that each item of information contained in the information disclosure statement submitted herein was cited for the first time in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

Respectfully submitted,

Date: December 12, 2001

  
\_\_\_\_\_  
Jason I. Garbell, Reg. No. 44,116  
Novozymes North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

#15/BM  
1/30/02

Attorney Docket No.: 5087.304-US

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Noguchi et al.

Confirmation No: 9126

Serial No.: 09/371,343

Group Art Unit: 1731

Filed: August 10, 1999

Examiner: Alvo, M.

For: Method For Producing Cellulose Derivatives

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(e)

Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. WO 89/08738
2. EP 0 383 999
3. WO 91/02839
4. WO 91/11553
5. US 4,923,656
6. US 5,871,730


It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

This information disclosure statement is being filed after the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution, but before, or simultaneously with, the payment of the issue fee.

In accordance with 37 C.F.R. § 1.97(e), Applicants enclose the statement specified in 37 C.F.R. § 1.97(e) and the fee set forth in 37 C.F.R. § 1.17(p). Please charge the fee, estimated to be \$180.00, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this petition is attached.

Respectfully submitted,

Date: December 12, 2001

  
\_\_\_\_\_  
Jason I. Garbell, Reg. No. 44,116  
Novozymes North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123